Table 2.

Univariate and MVA for pCR using clinical and genomic features including the RESP-HUM and UNTREATED-HUM signatures on the Hatzis and colleagues (28) dataset

UnivariateMultivariate
No. of patientsaPORAUCPORAUC
UNTREATED-HUM441<0.0012.57 (1.96–3.45)0.7400.0132.3 (1.21–4.52)0.879
RESP-HUM4410.0730.796 (0.618–1.02)0.5830.0581.45 (0.99–2.15)
PAM50 Proliferation441<0.0012.57 (1.9–3.56)0.7300.9170.96 (0.443–2.11)
ER
Negative175 (40%)10.5621
Positive266 (60%)<0.0010.234 (0.139–0.385)0.9920.99 (0.391–2.52)
PR
Negative227 (51%)10.467
Positive214 (49%)<0.0010.30 (0.176–0.51)0.6830.83 (0.363–1.97)
Clinical T stage
127 (6%)10.5711
2226 (51%)0.3640.652 (0.269–1.75)0.9020.92 (0.261–3.39)
3126 (29%)0.7460.854 (0.34–2.36)0.8440.87 (0.236–3.38)
462 (14%)0.0540.306 (0.0885–1.02)0.1950.35 (0.071–1.69)
Clinical grade
128 (6%)10.4811
2170 (39%)0.4982.05 (0.38–38.1)0.9671.05 (0.13–23.7)
3243 (55%)0.01911.1 (2.3–201)0.5742.02 (0.235–46.6)
PAM50
LumA141 (32%)10.6331
Basal167 (38%)<0.00118.2 (7.21–61.5)0.0265.76 (1.3–29.4)
Her224 (5%)0.0106.85 (1.51–31.1)0.1613.55 (0.59–21.7)
LumB67 (15%)0.0036.01 (1.92–22.6)0.4001.92 (0.438–9.49)
Normal42 (10%)0.0018.06 (2.39–31.7)0.00210 (2.34–47.6)
Hatzis signature SET index
1386 (88%)10.1361
236 (8%)0.0910.353 (0.0835–1.02)0.7291.34 (0.223–6.49)
319 (4%)0.3020.457 (0.0715–1.64)0.9530.94 (0.105–6.17)
Hatzis signature chemosensitive (RCB-I predict)
1296 (67%)10.5531
2145 (33%)<0.0012.97 (1.82–4.84)0.1271.76 (0.855–3.67)
Hatzis signature chemoresistance (RCB-III predict or 3-year survival)
1197 (45%)10.6031
2244 (55%)<0.0010.089 (0.0449–0.166)<0.0010.129 (0.0565–0.277)

NOTE: Univariate and MVAs were conducted using all Hatzis and colleagues (28) patients who received anthracycline and taxane chemotherapy only, and who had overall survival data (n = 441).

  • aThe number of patients with clinical ER status, PR status, T stage, grade, and pCR status available.